After reporting stellar data at ASH, Terns is acquired for $6.7bn.
ApexOnco Front Page
Recent articles
Dareon-Lung-1 will test obrixtamig plus Tecentriq and chemo in small-cell lung cancer.
And the company says it won’t need to carry out another trial.
Takeda picked up IBI363 for $1.2bn, and now Innovent advances IBI3026.
A fresh licensing deal tidies up years of work between the two companies.
And that could affect the drug's third-line accelerated approval.
The “next-gen” PF-07985045 is gone, but the group has another pan-KRAS shot.
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
